Lead Product(s) : Menaquinone-7,Ankascin 568-R
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Gnosis by Lesaffre
Deal Size : Undisclosed
Deal Type : Partnership
SunWay Biotech and Gnosis Launch MenaQ7® Metabolic Featuring ANKASCIN® 568-R Ingredient
Details : The partnership aims to launch SunWay's inaugural product, MenaQ7® Metabolic, featuring two key active ingredients, MenaQ7® Vitamin K2 as MK-7 and ANKASCIN® 568-R.
Product Name : MenaQ7
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
March 14, 2024
Lead Product(s) : Menaquinone-7,Ankascin 568-R
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Gnosis by Lesaffre
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Menaquinone-7
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Gnosis by Lesaffre
Deal Size : Undisclosed
Deal Type : Acquisition
Gnosis by Lesaffre Enhances Vitamin K2 Offering with Acquisition of NattoPharma
Details : This acquisition brings together globally recognized vitamin K2 brands vitaMK7® and MenaQ7® and allows Gnosis by Lesaffre to offer to the market the most complete portfolio of solutions, adapted to each market need and able to satisfy all customers.
Product Name : MenaQ7
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
May 25, 2021
Lead Product(s) : Menaquinone-7
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Gnosis by Lesaffre
Deal Size : Undisclosed
Deal Type : Acquisition